Medincell's Stock Drops 3.68% and Falls Below its Resistance at €28.72
The biotech company from Montpellier faces a tough session at midday, moving against the trend of a well-oriented Parisian market. The stock is among the most penalized in the SBF 120, after having technically broken through at the end of last week.
Medincell's stock falls by 3.68% to €27.24 during the session, while the SBF 120 index is up by 0.60%. The stock is among the steepest declines in the SBF 120, trailing behind Abivax, Eutelsat Communications, and SES. Despite having breached its €28.72 resistance last Friday, a level closely watched for several weeks, today's session has pushed the price back below this threshold, turning it into a technical ceiling to be reclaimed. Despite this setback, the stock still maintains a gain of 10.37% over the month and 63.21% over the year. The price remains above its three moving averages: MM20 at €27.06, MM50 at €24.67 (+10.42%), and MM200 at €25.30 (+7.67%). The RSI at 64 indicates a still positive momentum without reaching the overbought zone.
Two American Biotech Conferences in June and European Approval for Olanzapine LAI
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The company's scientific agenda remains busy. The management will participate in two American biotech conferences in June, as announced on May 27, enhancing visibility among specialized investors. On the pipeline front, the European Medicines Agency accepted on May 22 the marketing authorization application for olanzapine LAI, a long-acting subcutaneous injection developed with Teva for schizophrenia. This acceptance initiates the European evaluation phase of the flagship candidate of the partnership. Regarding price targets, Oddo raised its target to €52 in mid-May, representing a theoretical potential of about 91% compared to the current price. The support level at €22.86 remains the next reference threshold in case of an extended downward movement, while reclaiming €28.72 would signal the opposite.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
